Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Non-Small-Cell Lung Cancer · Metastatic Non-Small-Cell Lung Cancer · Advanced Non-Small-Cell Lung Cancer · EGFR P-Loop and Alpha C-Helix Compressing · EGFR PACC · EGFR Uncommon Mutations
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 480 (planned)
- Started
- Dec 17, 2025
- Main results expected
- Feb 2029
- Fully finished
- Dec 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS) determined by blinded independent central review (BICR)
Measured over: Until progression or death, assessed up to approximately 4 years
Confirmed overall response rate (ORR) as determined by BICR
Measured over: Until progression or death, assessed up to approximately 3 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07185997 · record last updated 2026-11-02 · checked 2026-11-09 15:47 UTC